---
layout: post
title: "Restless Legs Syndrome: A Review."
date:
author: "Habakuk Hain"
categories: transmission
tags: ["restless legs syndrome", "gabapentinoids", "dopamine agonist augmentation"]
image:
rating: 6
paper_title: "Restless Legs Syndrome: A Review."
paper_author: "Winkelman"
paper_journal: "JAMA"
paper_year: "2026"
paper_doi: "https://doi.org/10.1001/jama.2025.23247"
paper_et_al: true
summary: "This comprehensive JAMA review updates RLS management, highlighting the paradigm shift away from dopamine agonists as first-line therapy due to augmentation risk (7-10% annually) toward gabapentinoids, which show 70% response rates in RCTs. Key clinical pearls include treating iron deficiency when ferritin â‰¤100 ng/mL and recognizing RLS's high comorbidity with neurological conditions like MS (27.5%) and Parkinson's (20%)."
author_context: "Massachusetts General Hospital and Harvard Medical School sleep medicine and neurology experts"
---

**Problem**: This review addresses the need for updated RLS management guidelines given evolving evidence on treatment efficacy and augmentation risks.

**Result**: Gabapentinoids are now established as first-line therapy with superior long-term outcomes compared to dopamine agonists, which carry significant augmentation risk.

**Open Questions**: The optimal approach for treatment-resistant RLS and the role of low-dose opioids in refractory cases require further investigation.
